Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 上海医药
Other Market Stock Code601607
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameSH Pharma
Stock Code02607
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities本集團是中國領先的全國性垂直一體化醫藥公司,業務涵蓋製藥業務、醫藥分銷及供應鏈解決方案、藥品零售,覆蓋醫藥行業價值鏈主要環節。
Listing Date2011-05-20
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海浦東新區張江路92號
Business Address (Hong Kong)香港中環皇后大道中15號置地廣場告羅士打大廈8樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.pharm-sh.com.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 23.00 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2011-05-12 to 2011-05-12
Global Offering Shares664,214,000 shares
HK Public Offer Shares (Initial)33,210,800 shares (5.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)631,003,200 shares (95.0%)
Offer Ratio~5.0%
Total Shares Post-IPO2,656,857,338 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share28.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 15,276,922,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 10.57B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣1,368.3百萬元(權益持有者應享稅後利潤)
Period-End Cash Balance人民幣6,039.6百萬元
Listing Expenses~HK$ 520,000,000
Listing Expenses / Funds Raised~3.4%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 200820092010
Revenue 3,214,3984,343,3796,111,948
Cost of sales -2,932,159-4,002,539-5,633,842
Gross profit 282,239340,840478,106
Other income and gains, net 6,0325,10121,385
Selling and distribution expenses -89,254-109,504-165,105
Administrative expenses -72,250-78,429-105,740
Net finance costs -29,517-37,288-52,592
Share of associates and JVs 4,4039,16313,760
Profit before tax 101,653129,883189,814
Income tax expense -30,207-36,290-58,099
Profit for the year 71,44693,593131,715
Profit attributable to owners 45,90360,915104,807
Balance Sheet
Item 200820092010
Cash and cash equivalents 132,460334,934111,792
Trade and bills receivables 912,8141,338,2162,021,686
Inventories 469,117706,5071,451,626
Total current assets 1,649,9762,682,8823,789,557
Total assets 1,750,8232,789,8423,949,337
Total current liabilities 1,325,9252,000,8472,949,342
Total liabilities 1,333,0572,005,3952,953,139
Total equity 417,766784,447996,198
Equity attributable to owners 272,110606,113996,198
Interest-bearing borrowings 338,000946,6271,152,665
Cash Flow Statement
Item 2010
Net cash from operating activities -536,660
Net cash from investing activities -402,018
Net cash from financing activities 715,536
Net increase in cash -223,142
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 23.0
First Day OpenHK$ 23.25
First Day Change-48.22%
First Day Volume81571700.0
First Day Turnover1879790000.0
Use of Proceeds
1、所得款項凈額約40%(或約5,909百萬港元)預期將用于擴大及加強我們的分銷網絡及整合現有分銷網絡; 2、所得款項凈額約30%(或約4,432百萬港元)預期將用于戰略性收購中國國內及國際醫藥制造業務; 3、所得款項凈額約10%(或約1,477百萬港元)預期將用于產品研發平臺的投資,以進一步加強我們的產品組合及在研產品; 4、所得款項凈額約10%(或約1,477百萬港元)預期將用于信息技術系統及平臺的投資; 5、所得款項凈額剩余約10%(或約1,477百萬港元)預期將用于我們的營運資金需求及一般企業用途。

Underwriting Syndicate

Joint Sponsors (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 Deutsche Bank AG, Hong Kong Branch CE AAK077 Credit Suisse (Hong Kong) Limited CE AAO017
Overall Coordinators (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Deutsche Bank AG, Hong Kong Branch CE AAK077 Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Deutsche Bank AG, Hong Kong Branch CE AAK077 Credit Suisse (Hong Kong) Limited CE AAO017 中国国际金融香港证券有限公司 CE AEN894
Joint Lead Managers (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 Deutsche Bank AG, Hong Kong Branch CE AAK077 Credit Suisse (Hong Kong) Limited CE AAO017

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 GuoLine Capital Limited 388,483,800 HKD — 2.54% — 6 months 2011-11-20
2 淡马锡控股(私人)有限公司 2,330,909,700 HKD — 15.26% — 6 months 2011-11-20
3 国浩管理有限公司 776,969,900 HKD — 5.09% — 6 months 2011-11-20
4 美国辉瑞(香港)有限公司 388,483,800 HKD — 2.54% — 6 months 2011-11-20
5 中银集团投资有限公司 388,483,800 HKD — 2.54% — 6 months 2011-11-20

Directors & Management

PositionChinese nameEnglish Name
Chairman呂明方—
Company Secretary韓敏、莫明慧—
No director data available.

Major Shareholders

Major Shareholders & Holdings上實集團、上海上實、上藥集團及華源集團為主要股東。緊隨全球發售後(假設超額配售權未獲行使),上實集團持有A股914,958,047股(34.43%)及H股10,000,000股(0.38%);上海上實持有A股914,958,047股(34.43%);上藥集團及華源集團各持有A股752,008,452股(28.30%)。
About this page

This page shows SH Pharma (02607) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect